Abstract:Introduction: Achieving an ideal Tc-99m labeled nitroimidazole hypoxia marker is still considered to be of great interest. Metronidazole xanthate (MNXT) ligand was synthesized and radiolabeled with Tc-99m-glucoheptonate (GH) to form the (TcO)-Tc-99m-MNXT complex, for the potential use as a novel probe for imaging tumor hypoxia. Methods: For labeling, (TcO)-Tc-99m-MNXT was prepared by ligand-exchange reaction with Tc-99m-GH. The radiochemical purity of the (TcO)-Tc-99m-MNXT complex was measured by thin layer chromatography (TLC) and high performance liquid chromatography (HPLC). The distribution coefficient and stability of the complex was investigated. The structure of the (TcO)-Tc-99m-MNXT complex was verified by preparation and characterization of the corresponding stable rhenium complex. The cellular uptake of the (TcO)-Tc-99m-MNXT complex was determined in murine sarcoma 5180 cell lines under hypoxic and aerobic conditions. The biodistribution and single photon emission computed tomography (SPECT) image studies of the (TcO)-Tc-99m-MNXT complex were performed in mice bearing S 180 tumor. Results: The radiochemical purity of the (TcO)-Tc-99m-MNXT complex was over 90%. It had good in vitro stability and its distribution coefficient indicated that it was a hydrophilic complex. When Tc-99m and Re complexes were coinjected in HPLC, both radioactivity (for Tc-99m complex) and UV detectors (for Re complex) showed nearly identical HPLC profiles, suggesting their structures are similar. The tumor cell experiment and the biodistribution in mice bearing S 180 tumor showed that the (TcO)-Tc-99m-MNXT complex had a good hypoxic selectivity and accumulated in the tumor with high uptake and good retention. Single photon emission computed tomography (SPE') image studies showed that the tumor detection was observable. Conclusions: (TcO)-Tc-99m-MNXT is prepared from a kit without the need for purification and shows high tumor uptake, tumor/blood and tumor/muscle ratios, suggesting that it would be a promising candidate for imaging tumor hypoxia. (C) 2015 Elsevier Inc. All rights reserved.

Synthesis and Biological Evaluation of Novel 99Mtcn-Labeled Bisnitroimidazole Complexes Containing Monoamine-Monoamide Dithiol As Potential Tumor Hypoxia Markers

Synthesis, Radiolabeling and in Vivo Biological Evaluation of 99Mtc-Labeled MAG3-based Bisnitroimidazole Complexes As Tumor Hypoxia Markers

99Mtc/re Complexes Bearing Bisnitroimidazole or Mononitroimidazole As Potential Bioreductive Markers for Tumor: Synthesis, Physicochemical Characterization and Biological Evaluation

Synthesis and preliminary biological evaluation of the 99mTc labeled nitrobenzoimidazole and nitrotriazole as tumor hypoxia markers.

Preparation and biological evaluation of two novel 99mTc-nitrido complexes of metronidazole derivative for targeting hypoxia

Preparation and Bioevaluation of Novel 99Mtc-Labeled Complexes with a 2-Nitroimidazole HYNIC Derivative for Imaging Tumor Hypoxia

Novel 99mtc Labelled Complexes with 2-Nitroimidazole Isocyanide: Design, Synthesis and Evaluation As Potential Tumor Hypoxia Imaging Agents.

Radiosynthesis and Evaluation of Novel [99mtc(i)]+ and [99mtc(i)(co)3]+ Complexes with a 4‐nitroimidazole Isocyanide for Imaging Tumor Hypoxia

Synthesis and evaluation of [99mTcN]2+ core and [99mTcO]3+ core labeled complexes with 4-nitroimidazole xanthate derivative for tumor hypoxia imaging

Preparation and Biological Evaluation of Two Novel Tc-99m-nitrido Complexes of Metronidazole Derivative for Targeting Hypoxia

Preparation and Bioevaluation of a Novel 99Mtc-Labelled Propylene Amine Oxime (pnao) Containing Two 4-Methyl-2-nitroimidazole Groups As a Promising Tumor Hypoxia Imaging Agent

Synthesis And Biodistribution Of Novel Tc-99m Labeled 4-Nitroimidazole Dithiocarbamate Complexes As Potential Agents To Target Tumor Hypoxia

Synthesis and evaluation of [<SUP>99m</SUP>TcN]<SUP>2+</SUP> core and [<SUP>99m</SUP>TcO]<SUP>3+</SUP> core labeled complexes with 4-nitroimidazole xanthate derivative for tumor hypoxia imaging

Preparation and bioevaluation of a novel 99m Tc-labelled propylene amine oxime (PnAO) containing two 4-methyl-2-nitroimidazole groups as a promising tumor hypoxia imaging agent

In vitro and in vivo evaluation of technetium‐99m‐labeled propylene amine oxime complexes containing nitroimidazole and nitrotriazole groups as hypoxia markers

Biological Evaluation and SPECT Imaging of Tumor Hypoxia Using a Novel Technetium-99M Labeled Tracer with 2-Nitroimidazole Moiety

Synthesis of 99Mtc-Labeled 2-Mercaptobenzimidazole As a Novel Radiotracer to Diagnose Tumor Hypoxia.

Kit formulation for preparation and biological evaluation of a novel 99m Tc-oxo complex with metronidazole xanthate for imaging tumor hypoxia

Preparation and Biological Evaluation of a Technetium-99M Labeled 4-Nitroimidazole Derivative for Imaging Tumor Hypoxia

Synthesis and Evaluation of <SUP>99m</SUP>Tc-Labelled 2-Nitroimidazole Derivatives with Different Linkers for Tumour Hypoxia Imaging

Preparation and Biological Evaluation of 99Mtc-N4ipa for Single Photon Emission Computerized Tomography Imaging of Hypoxia in Mouse Tumor